Kathrin E. Witzke

Integrated Fourier Transform Infrared Imaging and Proteomics for Identification of a Candidate Histochemical Biomarker in Bladder Cancer.

Barbara Sitek, Martin Eisenacher, Katrin Marcus, 2019, The American journal of pathology.

Proteome profiling of enzalutamide‐resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration‐resistant prostate cancer

B. Sitek, B. Hadaschik, G. Kramer, 2022, International journal of cancer.

Plasma Proteomics Enable Differentiation of Lung Adenocarcinoma from Chronic Obstructive Pulmonary Disease (COPD)

B. Sitek, Y. Ko, T. Brüning, 2022, International journal of molecular sciences.

Comparative proteome analysis identified CD44 as a possible serum marker for docetaxel resistance in castration‐resistant prostate cancer

B. Sitek, B. Hadaschik, S. Shariat, 2021, Journal of cellular and molecular medicine.

Pancreatic cancer acquires resistance to MAPK pathway inhibition by clonal expansion and adaptive DNA hypermethylation

R. Lawlor, Christopher Schröder, M. Trajkovic-Arsic, 2024, Clinical epigenetics.

Epigenetic plasticity via adaptive DNA hypermethylation and clonal expansion underlie resistance to oncogenic pathway inhibition in pancreatic cancer

B. Sitek, A. Scarpa, R. Lawlor, 2022, bioRxiv.

Quantitative Secretome Analysis of Activated Jurkat Cells Using Click Chemistry-Based Enrichment of Secreted Glycoproteins.

B. Sitek, D. A. Megger, M. Eisenacher, 2017, Journal of proteome research.

Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer

B. Sitek, B. Hadaschik, G. Kramer, 2023, Prostate cancer and prostatic diseases.